• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Multidrug regimen boosts responses to bexarotene

Response rates to bexarotene in patients with cutaneousT-cell lymphoma can be improved with the use of combination therapy

Related Videos
Related Content
Derm In The News: September 29-October 5
October 5th 2024

Derm In The News: September 29-October 5

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

GPP Therapies: Comparing Efficacy and Safety of Secukinumab and Ustekinumab
October 4th 2024

GPP Therapies: Comparing Efficacy and Safety of Secukinumab and Ustekinumab

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Significant Proportion of Patients With AD Maintain Stable EASI With Tralokinumab Treatment
October 4th 2024

Significant Proportion of Patients With AD Maintain Stable EASI With Tralokinumab Treatment

9 Months of Treatment With Tralokinumab Results in Improved QoL, Itch, and Sleep
October 4th 2024

9 Months of Treatment With Tralokinumab Results in Improved QoL, Itch, and Sleep

© 2024 MJH Life Sciences

All rights reserved.